Breaking the time capsule: Life Sciences in 2010 and today
CRA’s Life Sciences Practice team recently analyzed past predictions of industry trends and compared them to what has occurred in the past decade, identified...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Mr. Lev Gerlovin has more than 20 years of consulting experience across strategic planning, litigation, and policy spheres. His recent focus has been in leading strategy engagements for a diverse set of clients, including major pharmaceutical and biotechnology manufacturers, distributors, health plan providers, and industry groups.
Mr. Gerlovin has managed projects spanning commercial strategy, pricing and market access, product design and optimization, product launch, portfolio lifecycle management, channels and distribution, sales and marketing effectiveness, and organizational design. He has broad therapeutic category experience, particularly in diabetes, endocrinology, neurology, psychiatry, hematology, oncology, immunology, rare diseases, and cell and gene therapy. He leads CRA’s Life Sciences 2030 Idea Leadership Platform.